Use of Molecular Tools to Identify Patients With Indolent Breast Cancers With Ultralow Risk Over 2 Decades

No abstract is available for this paper.

• Publication year

  2017

• Venue

  JAMA Oncology

• Publication date

  2017-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1001/jamaoncol.2017.1261PMID 28662222PMCID PMC5710197
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A breast cancer gene signature for indolent disease

  2017cited by this paper
• Breast Cancer Screening in Denmark

  2017cited by this paper
• Population-based screening for cancer: hope and hype

  2016cited by this paper
• 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.

  2016cited by this paper
• Long-term follow-up of a large active surveillance cohort of patients with prostate cancer.

  2015cited by this paper
• Identification of a Low-Risk Luminal A Breast Cancer Cohort That May Not Benefit From Breast Radiotherapy.

  2015cited by this paper
• Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial.

  2015cited by this paper
• Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update.

  2014cited by this paper
• A systematic assessment of benefits and risks to guide breast cancer screening decisions.

  2014cited by this paper
• JAMA patient page. Breast cancer screening: benefits and harms.

  2014cited by this paper
• Adherence to Endocrine Therapy in Breast Cancer Adjuvant and Prevention Settings

  2014cited by this paper
• Mammographic screening detects low-risk tumor biology breast cancers

  2014cited by this paper
• Long-term impact of the 70-gene signature on breast cancer outcome

  2014cited by this paper
• Addressing overdiagnosis and overtreatment in cancer: a prescription for change.

  2014cited by this paper
• Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343.

  2013cited by this paper
• Overdiagnosis and overtreatment in cancer: an opportunity for improvement.

  2013cited by this paper
• The benefits and harms of breast cancer screening: an independent review

  2013cited by this paper
• A diagnostic gene profile for molecular subtyping of breast cancer associated with treatment response

  2012cited by this paper
• Impact of mammographic screening on the detection of good and poor prognosis breast cancers

  2011cited by this paper
• Prognostic utility of HOXB13 : IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial

  2011cited by this paper
• Gene regulatory networks: a new conceptual framework to analyse breast cancer behaviour.

  2011cited by this paper
• Biologic markers determine both the risk and the timing of recurrence in breast cancer

  2011cited by this paper
• Overdiagnosis in cancer.

  2010cited by this paper
• Estrogen Receptor-α Phosphorylation at Serine 305, Nuclear p21-Activated Kinase 1 Expression, and Response to Tamoxifen in Postmenopausal Breast Cancer

  2010cited by this paper
• Recurrence and mortality dynamics for breast cancer patients undergoing mastectomy according to estrogen receptor status: Different mortality but similar recurrence

  2010cited by this paper
• Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer.

  2009cited by this paper
• Supervised risk predictor of breast cancer based on intrinsic subtypes.

  2009cited by this paper
• Rethinking screening for breast cancer and prostate cancer.

  2009cited by this paper
• Long-term follow-up of the randomized Stockholm trial on adjuvant tamoxifen among postmenopausal patients with early stage breast cancer

  2007cited by this paper
• Long-term pattern of disease recurrence among patients with early-stage breast cancer according to estrogen receptor status and use of adjuvant tamoxifen

  2007cited by this paper
• Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.

  2006cited by this paper
• Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer.

  2006cited by this paper
• Converting a breast cancer microarray signature into a high-throughput diagnostic test

  2006cited by this paper
• A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.

  2004cited by this paper
• Long-term effects of mammography screening: updated overview of the Swedish randomised trials.

  2002cited by this paper
• A gene-expression signature as a predictor of survival in breast cancer.

  2002cited by this paper
• Tumour dormancy: findings and hypotheses from clinical research on breast cancer.

  2001cited by this paper

• Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HR+/HER2- Early Breast Cancer 2025.

  2026cites this paper
• Differential prognostic impact of clinicopathologic factors for late recurrence in ER-positive breast cancer according to menopausal status.

  2026cites this paper
• Cryoablation: A Minimally Invasive Alternative for Early-Stage Breast Cancer: 6-Year Outcomes of the FROST Clinical Trial.

  2026cites this paper
• Multi-transcriptomics predicts clinical outcome in systemically untreated breast cancer patients with extensive follow-up

  2025cites this paper
• Adjuvant Radiation vs Endocrine Therapy After Lumpectomy for Early-Stage Breast Cancer in Older Women: Analysis of Real-World Survival Outcomes

  2025cites this paper
• Multimodality Treatment De-Intensification in Node-Negative, Hormone-Receptor Breast Cancer: What Are the Limits?

  2025cites this paper
• Less endocrine therapy in HR+/HER2- breast cancer: a nationwide trend despite unchanged guidelines

  2025cites this paper
• Identification of Early-Stage Breast Cancer with a Minimal Risk of Recurrence by the Breast Cancer Index

  2025cites this paper
• Long-Term Outcomes of Radiation Monotherapy Versus Combined Radiation Monotherapy + Hormone Therapy in Low-Risk Early-Stage Breast Cancer Patients 70 Years or Older After Breast-Conserving Surgery.

  2025cites this paper
• Gene Expression Signatures for Guiding Initial Therapy in ER+/HER2- Early Breast Cancer

  2025cites this paper
• Leveraging real-world evidence to personalize adjuvant therapy in HR+/HER2- early breast cancer

  2025cites this paper
• Personalized recurrence risk prediction in early-stage breast cancer through an integrative mathematical model based on MammaPrint®, radiotherapy, phenotype, and clinicopathological factors

  2025cites this paper
• Understanding Patient Experiences to Inform Future Studies to Optimize Personalization of Treatment for Early Breast Cancer

  2024cites this paper
• Ensemble‐based classification using microRNA expression identifies a breast cancer patient subgroup with an ultralow long‐term risk of metastases

  2024influential citation
• Gene Expression Assays to Tailor Adjuvant Endocrine Therapy for HR+/HER2− Breast Cancer

  2024cites this paper
• Precision Oncology in Breast Cancer Surgery.

  2024cites this paper
• A novel multiscale framework for delineating cancer evolution from subclonal compositions.

  2024cites this paper
• Differential long-term tamoxifen therapy benefit by menopausal status in breast cancer patients: secondary analysis of a controlled randomized clinical trial

  2024cites this paper
• Selection of Patients With Early-Stage Breast Cancer for Extended Endocrine Therapy: A Secondary Analysis of the IDEAL Randomized Clinical Trial.

  2024cites this paper
• MammaPrint Genomic Assay Providing Prognostic Information in Early Breast Cancer: 10-Year Follow-Up From a Retrospective German Breast Cancer Registry Analysis

  2024cites this paper
• Multi-modal AI for comprehensive breast cancer prognostication

  2024cites this paper
• Innovation in cancer pharmacotherapy through integrative consideration of germline and tumor genomes.

  2024cites this paper
• GATA3 and markers of epithelial-mesenchymal transition predict long-term benefit from tamoxifen in ER-positive breast cancer

  2024influential citation
• Hormone Deprivation-Free Survival-Inequities Persist in Research Priorities for Patients With Cancer.

  2024cites this paper
• Utility of the 70-Gene MammaPrint Assay for Prediction of Benefit From Extended Letrozole Therapy in the NRG Oncology/NSABP B-42 Trial

  2024cites this paper
• Selecting postoperative adjuvant systemic therapy for early‐stage breast cancer: An updated assessment and systematic review of leading commercially available gene expression assays

  2024influential citation
• Impact of Prosigna test on adjuvant treatment decision in lymph node-negative early breast cancer—a prospective national multicentre study (EMIT-1)

  2024cites this paper
• Breast Cancer with HER2 IHC 2+ and Average HER2 Signals/Cell ≥ 6 and HER2/CEP17 Ratio < 2: A Multi-Institutional Cohort Analysis Emphasizing Outcome and Molecular Subtype.

  2024cites this paper
• Lessons from other fields of medicine, Part 1: Breast cancer.

  2023cites this paper
• Optimal adjuvant therapy in older (≥70 years of age) women with low-risk early-stage breast cancer

  2023cites this paper
• Luminal breast cancer identity is determined by loss of glucocorticoid receptor activity

  2023cites this paper
• 5-year adherence to adjuvant endocrine treatment in Dutch women with early stage breast cancer: A population-based database study (2006–2016)

  2023cites this paper
• Evaluation of intraoperative breast radiotherapy on local recurrence: a Brazilian cohort

  2023cites this paper
• Breast cancer survival and incidence of second primary cancers after 30 years in a randomized study of two versus five years of adjuvant tamoxifen therapy

  2023cites this paper
• The long-term psychosocial consequences of screen-detected ductal carcinoma in situ and invasive breast cancer

  2023cites this paper
• Cost-Effectiveness Analysis of MammaPrint® to Guide the Use of Endocrine Therapy in Patients with Early-Stage Breast Cancer

  2023influential citation
• Time to Surgery in Breast Cancer-Is Faster Always Better?

  2023cites this paper
• Increased Early Cancer Diagnosis: Unveiling Immune-Cancer Biology to Explain Clinical “Overdiagnosis”

  2023cites this paper
• Ten-year follow-up of the observational RASTER study, prospective evaluation of the 70-gene signature in ER-positive, HER2-negative, node-negative, early breast cancer.

  2022cites this paper
• Outcome of Patients With an Ultralow-Risk 70-Gene Signature in the MINDACT Trial

  2022influential citation
• Terapia personalizada en cáncer de mama precoz. Implicancias prácticas

  2022cites this paper
• How we treat HR-positive, HER2-negative early breast cancer.

  2022cites this paper
• Características clínico-patológicas y supervivencia de pacientes con cáncer de mama de riesgo muy bajo

  2022cites this paper
• Clinical and molecular characteristics of estrogen receptor‐positive ultralow risk breast cancer tumors identified by the 70‐gene signature

  2022influential citation
• HER2-low breast cancers: incidence, HER2 staining patterns, clinicopathologic features, MammaPrint and BluePrint genomic profiles

  2022cites this paper
• Clinicopathological characteristics and survival results of patients with ultralow risk breast cancer.

  2022cites this paper
• Intratumoral in vivo staging of breast cancer by multi-tracer PET and advanced analysis

  2022cites this paper
• Limiting systemic endocrine overtreatment in postmenopausal breast cancer patients with an ultralow classification of the 70-gene signature

  2022influential citation
• Effects of awareness of breast cancer overdiagnosis among women with screen-detected or incidentally found breast cancer: a qualitative interview study

  2022cites this paper
• Countercurrents: DCIS or Cancer? Why All the Confusion?

  2022cites this paper
• Why It Is Time to Challenge Entrenched Beliefs About Breast Cancer Screening

  2022cites this paper
• Copy number heterogeneity identifies ER+ breast cancer patients that do not benefit from adjuvant endocrine therapy

  2022cites this paper
• Firmas génicas en el cáncer de mama

  2022cites this paper
• Validation of the 70-gene signature test (MammaPrint) to identify patients with breast cancer aged ≥ 70 years with ultralow risk of distant recurrence: A population-based cohort study.

  2022cites this paper
• Keynote Address at the ASBrS 2022 Annual Meeting Low-Risk Breast Cancer: When Is Local Therapy Enough?

  2022cites this paper
• The Current Staging and Classification Systems of Breast Cancer and Their Pitfalls: Is It Possible to Integrate the Complexity of this Neoplasm into a Unified Staging System?

  2022cites this paper
• Focal Therapy for Prostate Cancer: Evolutionary Parallels to Breast Cancer Treatment

  2022cites this paper
• Prognostic and Predictive Significance of Stromal Tumor-Infiltrating Lymphocytes (sTILs) in ER-Positive/HER2−Negative Postmenopausal Breast Cancer Patients

  2022cites this paper
• Combined 70- and 80-gene signatures identify tumors with genomically luminal biology responsive to neoadjuvant endocrine therapy and are prognostic of 5-year outcome in early-stage breast cancer.

  2022cites this paper
• Radiation in Early-Stage Breast Cancer: Moving beyond an All or Nothing Approach

  2022cites this paper
• IP6K2 predicts favorable clinical outcome of primary breast cancer

  2021cites this paper
• A world‐wide survey on kidney transplantation practices in breast cancer survivors: The need for new management guidelines

  2021cites this paper
• MammaPrint and BluePrint comprehensively capture the cancer hallmarks in early‐stage breast cancer patients

  2021cites this paper
• MCM3 upregulation confers endocrine resistance in breast cancer and is a predictive marker of diminished tamoxifen benefit

  2021cites this paper
• Identification and characterization of a 25-lncRNA prognostic signature for early recurrence in hepatocellular carcinoma

  2021cites this paper
• Comparison of the Metastasis Predictive Potential of mRNA and Long Non-Coding RNA Profiling in Systemically Untreated Breast Cancer

  2021cites this paper
• Peripheral Blood-Based Gene Expression Studies in Schizophrenia: A Systematic Review

  2021cites this paper
• The WISDOM study: a new approach to screening can and should be tested

  2021cites this paper
• Solving current dilemmas in the adjuvant endocrine treatment of pre- and perimenopausal women with an estrogen receptor positive breast cancer

  2021cites this paper
• Management of Early Stage Breast Cancer: Basics and Controversies

  2021cites this paper
• The Importance of Clinical Data for the Diagnosis of Breast Tumours in North Afghanistan

  2021cites this paper
• A Multi- institutional Prospective Analysis of Impact of CanAssist Breast (Morphometric Immunohistochemistry Based Test) on Adjuvant Chemotherapy Decisions in Early Breast Cancer

  2021cites this paper
• Epigenetic Reprogramming and Landscape of Transcriptomic Interactions: Impending Therapeutic Interference of Triple-Negative Breast Cancer in Molecular Medicine.

  2021cites this paper
• Proteomics provides individualized options of precision medicine for patients with gastric cancer

  2021cites this paper
• Outcome without any adjuvant systemic treatment in stage I ER+/HER2- breast cancer patients included in the MINDACT trial.

  2021cites this paper
• The cost impact of unselective vs selective MammaPrint testing in early-stage breast cancer in Southern Africa

  2021cites this paper
• Assessment of 25-Year Survival of Women With Estrogen Receptor–Positive/ERBB2-Negative Breast Cancer Treated With and Without Tamoxifen Therapy

  2021cites this paper
• Gene Expression Profiling Tests for Early-Stage Invasive Breast Cancer: A Health Technology Assessment.

  2020cites this paper
• Pragmatic Trials and Approaches to Transforming Care

  2020cites this paper
• Assays of Genetic Expression in Tumor Tissue as a Technique to Determine Prognosis In Patients With Breast Cancer

  2020cites this paper
• ArticleLow Prevalence of HER

  2020cites this paper
• A clinical validation study of MammaPrint in hormone receptor-positive breast cancer from the Austrian Breast and Colorectal Cancer Study Group 8 (ABCSG-8) biomarker cohort.

  2020cites this paper
• Clinical and Molecular Characteristics of ER-Positive Breast Cancer Tumors Identi�ed as Ultralow Risk by the 70-Gene Signature in a Randomized Clinical Trial

  2020influential citation
• Impact of Indolent Schistosomiasis on Morbidity and Mortality from Respiratory Tract Infections in Preschool Age Children from a Schistosomiasis Endemic Area.

  2020cites this paper
• Genetic platforms: Do we do what we know? or do we know what we do?

  2020cites this paper
• Risk Stratification for Adjuvant Treatment in Early Breast Cancer

  2020cites this paper
• The Evolution of Our Understanding of the Biology of Cancer Is the Key to Avoiding Overdiagnosis and Overtreatment

  2020influential citation
• Low Prevalence of HER2-Positive Breast Carcinomas among Screening Detected Breast Cancers

  2020cites this paper
• Breast Cancer Assays of Genetic Expression in Tumor Tissue 09/01/19

  2020cites this paper
• We need more evidence to answer questions about screening

  2020cites this paper
• Systems Biology and Kidney Disease.

  2020cites this paper
• Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2019cites this paper
• Increased Mortality Risk among Early Stage Hormone Receptor Positive Breast Cancer Patients Who Did Not Receive Adjuvant or Neoadjuvant Therapy

  2019cites this paper
• Should we rename low risk cancers?

  2019cites this paper
• Mammaprint™: a comprehensive review.

  2019cites this paper
• Comprehensive Transcriptomic Profiling Identifies Breast Cancer Patients Who May Be Spared Adjuvant Systemic Therapy

  2019cites this paper
• Multigene Expression Signatures in Early Hormone Receptor Positive HER 2 Negative Breast Cancer

  2019cites this paper
• Assays of Genetic Expression in Tumor Tissue as a Technique to Determine Prognosis in Patients with Breast Cancer Effective : February 1 , 2019

  2019cites this paper
• Available and emerging molecular markers in the clinical management of breast cancer

  2019cites this paper
• Landmark Trials in Breast Cancer

  2019cites this paper